{"pub": "breitbart", "url": "https://breitbart.com/news/pfizer-lifts-profit-forecast-as-results-top-expectations", "downloaded_at": "2019-10-29 15:11:23.279731+00:00", "title": "Pfizer lifts profit forecast as results top expectations", "language": "en", "text": "New York (AFP) \u2013 Pfizer lifted its full-year profit forecast Tuesday following a better-than-expected third quarter on growth in its biopharma business.\n\nNet income jumped 87 percent to $7.7 billion, boosted by a one-time gain connected to a joint venture transaction with GlaxoSmithKline on consumer drugs.\n\nRevenues dipped 4.6 percent to $12.7 billion.\n\nStrong sellers for the big drugmaker included Ibrance, which treats breast cancer, and Xeljanz, which is used to treat rheumatoid arthritis and ulcerative colitis.\n\nHigher sales for these drugs helped offset the hit from lost patents for Viagra and other medications.\n\nBesides the transaction on consumer health, which closed on August 1, Pfizer has also announced that it will combine its off-patent Upjohn business with generics giant Mylan in a transaction expected to close next year.\n\n\u201cFollowing the expected close of the Upjohn-Mylan transaction next year, Pfizer RemainCo will be a smaller, science-based company with a singular focus on innovation,\u201d said Chief Executive Albert Bourla.\n\nPfizer lifted its full-year profit forecast and the midpoint of its 2019 revenue forecast.\n\nShares rose 3.0 percent to $38.39 in pre-market trading.", "description": "New York (AFP) \u2013 Pfizer lifted its full-year profit forecast Tuesday following a better-than-expected third quarter on growth in its biopharma", "authors": [], "top_image": "https://media.breitbart.com/media/2019/10/wi/afp/29/747473_pfizer-lifted-its-year-profit-forecast-expected-quarter-on-growth-in-its-640x335.jpg", "published_at": "2019-10-29"}